Lilly to sell Zepbound through telehealth platform Ro
Contributor since / Followers
JHVEPhoto/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) plans to streamline patient access to its weight-loss drug Zepbound by offering single-dose vials through telehealth platform Ro.
The vials will be made available through an integration with Lilly’s (LLY) LillyDirect self-pay pharmacy channel. The drugs will be prescribed by a Ro-affiliated healthcare provider, according to a Ro statement.
News of the Ro partnership appeared to weigh on Hims & Hers Health (HIMS), with shares sliding 5% in morning trading. Hims (HIMS) has been offering a compounded version of Zepbound, also known as tirzepatide, though its telehealth website.
Shares of Lilly (LLY) were down 1% Wednesday morning. The company also reported data for its breast cancer drug candidate imlunestrant.